Combined analysis of CNA, WES and TC-NGS (Fig. 2) showed CDKN2A deletion to be present in 60% of tumours; BAP1 mutated or deleted in 54%; RASSF7 amplification in 33%; RB1 deleted or mutated in 26%; NF2 mutated in 20%; TP53 mutated in 8%; SETD2 in 6%; DDX3X in 5% and LATS2 in 5%. This evidence concerns the gene LATS2 and neoplasm.